Comparing the current results to its competitors, 23andme Holding Co reported Revenue decrease in the 1 quarter 2025 year on year by -37.92 %, despite the revenue increase by the most of its competitors of 9.25 %, recorded in the same quarter.
23andme Holding Co's Comment on Competition and Industry Peers
The company operates in a competitive personal genetics market that includes diagnostic and laboratory service providers, as well as new entrants offering direct access or consumer self-pay tests and genetic interpretation services, some of which may not comply with FDA regulations. Competitors may have longer operating histories and greater resources, allowing them to respond more quickly to new technologies, conduct extensive research and development, implement broader marketing campaigns, and adopt aggressive pricing and regulatory strategies. This competition may result in the development of similar or more widely accepted products and services by competitors, potentially attracting customers and reducing the company's market share. Success in this market depends on factors such as the size of the customer base, timing and market acceptance of products, customer service, marketing efforts, product usability, performance, price, reliability, and brand strength. The healthcare and telehealth markets are highly competitive and rapidly evolving, with increasing participation from new entrants, established telehealth providers, and traditional healthcare providers.
September 3, 2024
In the hallowed halls of biomedical discourse, where the delicate dance of science and medicine forswears the mundane for the miraculous, a singular name has emerged from the shadows of apprehension into the radiant light of hopeful endeavor 23andMe. With the forthcoming gathering of minds at the illustrious ESMO Congress in the year of our Lord 2024, the representatives of said enterprise are poised to unveil anticipatory findings pertaining to their clinical immuno-oncology programs, specifically numbered 23ME-00610 and 23ME-01473.As the sun rises upon the realms of renal cancer and the learned cohorts of Tumor Mutation Burden-High (TMB-H) and Microsatellite Instability-High (MSI-H), eager eyes shall scrut...
June 28, 2024
In a bold move poised to redefine preventive healthcare, 23andMe Holding Co. (Nasdaq: ME) and Nightingale Health Plc have joined forces to test an innovative blood metabolomics panel. This collaboration aims to leverage Nightingale Health s clinically-validated biomarkers with 23andMe s extensive genetic database, unlocking new potentials for individualized health risk predictions and personalized health interventions. Context and Collaboration Goals23andMe, a dominant player in the domain of consumer genetics and preventive healthcare, has long been a pioneer in empowering individuals with knowledge about their genetic makeup. This knowledge has been instrumental in facilitating personalized lifestyle and ...
June 3, 2024
In recent groundbreaking developments, 23andMe Holding Co., a prominent human genetics and biopharmaceutical company, has made significant strides in its mission to revolutionize cancer treatment. The company s latest announcements reveal positive preliminary results for their investigational drugs, 23ME-00610 and 23ME-01473, targeting CD200R1 and ULBP6, respectively. With the potential to transform cancer therapy, these advancements signify the power of genetic validation and personalized medicine in the fight against this devastating disease.23ME-00610 Monotherapy: Promising Clinical BenefitDuring the 2024 ASCO Annual Meeting, 23andMe Therapeutics presented encouraging preliminary findings for 23ME-00610. ...
May 29, 2024
Largest Study on LRRK2 Variant leads to Discoveries about Health, Ancestry, and History, as 23andMe Continues Expanding Biopharmaceutical EffortsIn a groundbreaking endeavor, leading human genetics and biopharmaceutical company, 23andMe Holding Co., has announced the findings of their largest study on the LRRK2 variant, shedding light on its impact on health, ancestry, and history. The results, published in the renowned scientific journal Brain, bring forth crucial insights into the complex relationship between genetics and Parkinson s disease, elevating our understanding of this debilitating condition.The study, conducted by 23andMe s robust research team, examined genetic data from a vast cohort of individ...
May 14, 2024
Fostering their commitment to making prescription medication more accessible and affordable, Lemonaid Health, a leading digital healthcare provider, has recently upped their services game by introducing a powerful erectile dysfunction medication in their product list. In a potentially monumental collaboration with Petros Pharmaceuticals, Lemonaid Health now offers STENDRA, a fast-acting erectile dysfunction (ED) tablet, to its customers. This newly minted partnership is welcomed news for men suffering from ED. With STENDRA s substantial efficacy and speed, it promises to offer significant relief from ED, putting it into work as quickly as 15 minutes before sexual activity. This breakthrough, courtesy of Petr...
March 6, 2024
23andMe Launches New Genetic Reports on Common Forms of Cancer23andMe, the leading direct-to-consumer genetic testing company, has taken a major step forward in personalized healthcare with the launch of new genetic reports on common forms of cancer. Customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through these reports, which are based on polygenic risk scores (PRS) developed by 23andMe.The introduction of these new reports underscores 23andMe s commitment to providing individuals with valuable genetic information that can help them make more informed decisions about their health. By analyzing thousands of genetic markers linked to cancer risk...
23andMe is Stepping Up its Targeted Cancer Therapies Despite Falling Revenue The genetic testing and research company 23andMe, is expanding its Phase 1/2a clinical trial, 23ME-00610, by enrolling 30 additional patients with advanced neuroendocrine and ovarian cancer. The trial is studying the investigational antibody called CD200R1 a potential harbinger of innovative targeted cancer treatments. This strategic decision comes at a crucial time when the American biotech firm s Q3 2023 revenues have paintively shrunk by 34.27%, however, it s noteworthy that this downturn aligns with the market scenario as the overall revenue of the company s competitive cohort has seen a similar, year-on-year drop....
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
Prenetics Global Limited is a company that operates in the field of personalized healthcare by offering genetic testing services to individuals. The company partners with healthcare providers and insurance companies to provide insights and recommendations based on genetic information, aiming to empower individuals to make informed decisions about their health.
Sources:
23andme Holding Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 23andme Holding Co versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
